Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01662362 · ClinicalTrials.gov registry record · NA
Abbott ESA Chagas Assay Post-Market Study
A NA study, sponsored by Abbott Diagnostics Division.
- Completed
- Registry status
- NA
- Development phase
- 63
- Enrollment target
NCT01662362: Completed NA study, sponsored by Abbott Diagnostics Division.
NCT01662362 is a NA study that has completed, run by Abbott Diagnostics Division. The registered enrollment target is 63 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01662362, a NA study, has completed, sponsored by Abbott Diagnostics Division.
- COMPLETED
- Registry status
- NA
- Development phase
- 63 participants
- Enrollment target
Study Summary
The study is conducted to meet an FDA post market commitment to collect and report data on the performance of the ESA Chagas assay. A minimum of 50 donor specimens that are FDA-licensed ABBOTT PRISM Chagas repeatedly reactive (RR)will be tested with the ABBOTT ESA Chagas assay. In addition, minimum of 300 ABBOTT PRISM Chagas nonreactive (NR) unidentified donor specimens will be tested with ABBOTT ESA Chagas assay.
Interventions
- DEVICE Testing Donor Specimens with ESA Chagas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2012-07 |
| Est. Completion | 2012-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01662362
The ClinicalTrials.gov registry entry for NCT01662362 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 63 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott Diagnostics Division, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Testing Donor Specimens with ESA Chagas is the first listed.
NCT01662362 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01662362 about?
NCT01662362 is a clinical study titled "Abbott ESA Chagas Assay Post-Market Study". The study is conducted to meet an FDA post market commitment to collect and report data on the performance of the ESA Chagas assay. A minimum of 50 donor specimens that are FDA-licensed ABBOTT PRISM Chagas repeatedly reactive (RR)will be tested with the ABBOTT ESA Chagas assay. In addition, minimum ...
What is the current status of trial NCT01662362?
This trial is currently completed. It is a NA study. The enrollment target is 63 participants. The study started on 2012-07. Estimated completion is 2012-12.
What interventions are being tested in trial NCT01662362?
The interventions under investigation include: Testing Donor Specimens with ESA Chagas (DEVICE).
Who is sponsoring clinical trial NCT01662362?
This trial is sponsored by Abbott Diagnostics Division, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.